Unmet Needs and Key Takeaways for Community Oncologists

Why It Matters

The sequencing gaps hinder evidence‑based decisions, potentially affecting survival and cost for patients. Integrating genomics and PSMA imaging equips community practices to deliver personalized, guideline‑aligned care.

Key Takeaways

• Chemotherapy sequencing with ARPI+ADT remains unanswered by current trials
• Radiopharmaceutical timing after docetaxel shows hypothesis‑generating benefit
• Routine HRR genetic testing now guideline‑driven for advanced prostate cancer
• PSMA‑PET imaging essential across diagnosis, staging, and treatment monitoring

Pulse Analysis

Prostate cancer treatment has entered a nuanced era where androgen‑receptor pathway inhibitors (ARPIs) are often introduced alongside androgen‑deprivation therapy (ADT) at diagnosis. While docetaxel has long been a cornerstone, the lack of prospective data on adding it to an ADT + ARPI regimen creates a decision‑making vacuum for community oncologists. The existing ARCHES and PEACE‑1 trials, built around an ARPI‑plus‑docetaxel backbone, cannot answer whether the triple combination yields incremental survival gains, leaving clinicians to balance potential toxicity against unproven benefit.

Parallel to chemotherapy, radiopharmaceuticals such as lutetium‑177‑PSMA are reshaping later‑line therapy. Early signals suggest that administering chemotherapy before lutetium may confer an advantage, yet the trial design suffered from asymmetric crossover, with many patients receiving lutetium after docetaxel but few the reverse. This methodological flaw renders the findings hypothesis‑generating rather than practice‑changing, underscoring the need for rigorously controlled sequencing studies to define the optimal treatment algorithm.

Amid these therapeutic ambiguities, precision tools are gaining traction. Updated 2026 guidelines now mandate comprehensive homologous recombination repair (HRR) genetic testing for all advanced prostate cancer patients, enabling targeted PARP‑inhibitor use where appropriate. Simultaneously, PSMA‑PET imaging has become indispensable for accurate staging, response assessment, and selection of radioligand therapy. For community oncologists, embracing these genomic and imaging advances offers a concrete pathway to deliver individualized, guideline‑concordant care despite lingering uncertainties in treatment sequencing.